Benjamin Rayner
Has grant
Senior Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Investigating the role of LOXL2/MAOB/MPO in cardiac ischemia reperfusion injury
Open Date: 2016-12-01
Close Date: 2019-12-01
Grant: Close
DNA traps - a new pathway to atherosclerosis
Open Date: 2016-01-01
Close Date: 2016-12-01
Grant: Close
Investigating the molecular mechanisms of remote pre- and post-conditioning within the setting of cardiac ischemia reperfusion injury
Open Date: 2013-12-01
Close Date: 2015-12-01
Grant: Close
Investigating the role of Egr-1 within the setting of cardiac preconditioning
Open Date: 2012-01-01
Close Date: 2012-12-01
Grant: Close
Investigating the effects of synthetic antioxidant supplementation on myocardial ischemia reperfusion injury
Open Date: 2005-11-01
Close Date: 2008-01-01
Articles (2)
Aberrant epigenetic regulation is a hallmark of Diffuse Midline Glioma (DMG), an incurable pediatric brain tumor. The H3K27M driver histone mutation leads to transcriptional dysregulation, indicating that targeting the epigenome and transcription may be key therapeutic strategies against this highly aggressive cancer. One such target is the Facilitates Chromatin Transcription (FACT) histone chaperone. We found FACT to be enriched at developmental gene promoters, coinciding with regions of open chromatin and binding motifs of core DMG regulatory transcription factors. Furthermore, FACT interacted and co-localized with the Bromodomain and Extra-Terminal Domain (BET) protein BRD4 at promoters and enhancers, suggesting functional cooperation between FACT and BRD4 in DMG. In vitro , a combinatorial therapeutic approach using the FACT inhibitor CBL0137, coupled with BET inhibition revealed potent and synergistic cytotoxicity across a range of DMG cultures. These results were recapitulated in vivo , significantly extending survival in three independent orthotopic PDX models of DMG. Mechanistically, we show that CBL0137 treatment decreased chromatin accessibility, synergizing with BET inhibition to cause broad transcriptional collapse, silencing several key oncogenes including MYC, PDGFRA , MDM4 and SOX2 , as well as causing alterations to the splicing landscape. Notably, this combination also elicited immune-related effects, including activation of the interferon response and antigen presentation mechanisms in DMG cells and induction of an activated state in macrophages and T cells, as demonstrated in an immunocompetent setting with spatial transcriptomics. Altogether, our data highlights the therapeutic promise of simultaneously targeting FACT and BET proteins in DMG, offering a dual tumor-intrinsic and immune-mediated strategy for combating this devastating pediatric brain tumor.
Year:
2024
Year:
2023
Collaborators (13)
Marcel Dinger
Dean
University of Sydney
Fatima Valdes-Mora
Team Leader
Children's Cancer Institute Australia
David Ziegler
Professor
University of New South Wales
David Lewis Lawrence
Conjoint Lecturer
UNSW Sydney
Maria Tsoli
Senior Scientist
Children's Cancer Institute Australia
Timothy N. Phoenix
Assistant Professor
University of Cincinnati
Mark Ledwidge
Research Director
Trinity College Dublin
Lana McClements
Associate Professor
University of Sydney
Holly Holliday
Children's Cancer Institute Australia
Robert Weatheritt
Associate Professor
UNSW Sydney
Chelsea Mayoh
Children's Cancer Institute Australia
Kristine McGrath
Senior Lecturer
University of Sydney
CHI KIN IP
Children's Cancer Institute Australia
Make your next move.
Prepare your application
Review drafts before you send them.